VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN. Int. J. Pharm. Sci. Drug Res. 2017, 9 (5), 224-227. https://doi.org/10.25004/IJPSDR.2017.090504.